Latest Biotech News

A phase 3 ENGOT-ENG-NSGO/GOG-3031/RUBY update showed durable disease control with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer. At a median follow-up of 55.6 months, 4-year...

The FDA approved datopotamab deruxtecan (Dato-DXd; Datroway) for unresectable or metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 inhibitor therapy. The...

A University of Pennsylvania and Children’s Hospital of Philadelphia case study highlighted meaningful clinical benefits from an mRNA-based CRISPR base-editing approach in an infant with CPS1...

Parabilis moved to the public markets with an IPO filing a day after signing an up-to-$2.3 billion-plus Regeneron collaboration. The Helicon-based antibody-drug conjugate platform deal centers on...

US policy pressure is building around outbound capital flows into China biotech, with lawmakers urging restrictions. A GOP lawmaker asked the Trump administration to curb China biotech deals,...

Researchers unveiled a prognostic nomogram designed to predict early outcomes in childhood aplastic anemia for patients treated with cyclosporine monotherapy. The model targets a long-standing...

AbbVie began another round of layoffs tied to its Allergan footprint, issuing a WARN notice for 85 permanent job cuts at its Irvine, California site. The company framed the actions within its eye...

Cenevo launched an AI-enabled inventory search capability for its Mosaic connected-lab platform, designed to let scientists query labware and stored samples using natural language. The feature,...

The FDA cleared AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Datroway for first-line treatment of triple-negative breast cancer (TNBC) when patients are not candidates...

The EMA’s Committee for Medicinal Products for Human Use recommended Boehringer Ingelheim’s nerandomilast, branded as Jascayd, as a replacement option as generic nintedanib (Ofev) approaches the...

The FDA approved Gilead’s hepatitis D therapy Hepcludex (bulevirtide) roughly four years after the agency rejected the drug earlier, citing manufacturing and distribution concerns. The approval...

Researchers at Sanford Burnham Prebys and collaborators at the University of Illinois Chicago reported in Science Advances that phosphoinositide kinases PI5P4Ks help regulate cholesterol...

A University of Pennsylvania and Children’s Hospital of Philadelphia report that an mRNA-based CRISPR base editing therapy delivered to infant “Baby KJ” with CPS1 deficiency produced meaningful...

Parabilis filed for an initial public offering on the heels of a strategic research collaboration with Regeneron. The partnership spans up to $2.3 billion in potential payments and covers...

QEt’s proposed €5 billion cross-sector growth fund is positioned to address European biotech’s funding shortfall by creating another homegrown route for growth capital. The initiative is framed...

China’s new rules for investigator-initiated trials (IITs) are expected to tighten oversight while legitimizing pathways for modalities beyond cell and gene therapies, according to reporting on...

Ahead of the 2026 ASCO Annual Meeting, organizers lifted the pre-meeting embargo on May 21 and highlighted multiple trial readouts across lung, gastrointestinal, and genitourinary cancers. The...

Vizgen laid off an unspecified number of employees as part of a strategic reorganization, according to company statements and employee reports. The spatial technology company said it is investing...

The FDA has approved datopotamab deruxtecan (Datroway; Dato-DXd) as a first-line option for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for...

Gilead won US approval for its hepatitis D drug Hepcludex (bulevirtide) after the FDA previously rejected the therapy roughly four years earlier. The agency cited manufacturing and distribution...